Last reviewed · How we verify
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously in Patients With Autism
The intent of this clinical study is to answer the questions: 1. Is the proposed treatment safe 2. Is treatment effective in improving the disease pathology of patients with Autism.
Details
| Lead sponsor | Ageless Regenerative Institute |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | WITHDRAWN |
| Start date | 2016-10 |
| Completion | 2018-01 |
Conditions
- Autism
Interventions
- Fat Harvesting and Stem Cell Injection
Primary outcomes
- Improvement in the Childhood Autism Rating Scale,CARS — 3 months
- Improvement in the Clinical Global Impression Scale, CGI — 3 months
- Improvement in the Childhood Autism Rating Scale,CARS — 6 months
- Improvement in the Clinical Global Impression Scale, CGI — 6 months
Countries
United States